Expert consensus on diagnosis of B cell chroniclymphoproligerative disorders in China 2014 Rituximab Expression of CD20 antigen As a single agent New 375mg/m2 weekly ×4-8 CR 64% Replase 375mg/m2 weekly ×4-8 CR 53% As a combination New 375mg/m2 weekly ×4-8 CR 100% Treatment algorithm BRAF mutation Tiacci in 2009 fist described in melanoma 100% harbored BRAF V600E mutation orign? Vemurafenib inducing hairy cells apoptosis Vemurafenib phase 2 multicenter study early replase, refractory to PA,bone marrow hypop
原创力文档

文档评论(0)